Last reviewed 2026-04-22 · How we verify

AXS-07 (meloxicam-rizatriptan)

AXS-07 combines meloxicam (an NSAID) with rizatriptan (a 5-HT1B/1D receptor agonist) to treat acute migraine by reducing inflammation and constricting cranial blood vessels.

AXS-07 combines meloxicam (an NSAID) with rizatriptan (a 5-HT1B/1D receptor agonist) to treat acute migraine by reducing inflammation and constricting cranial blood vessels. Used for Acute migraine with or without aura.

At a glance

Mechanism of action

Meloxicam inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin-mediated inflammation and pain signaling. Rizatriptan acts as a selective agonist at serotonin 5-HT1B and 5-HT1D receptors on cranial blood vessels and trigeminal nerve terminals, causing vasoconstriction and suppressing pain transmission. The combination leverages both anti-inflammatory and vasoconstrictor mechanisms for enhanced migraine relief.

Approved indications

• Acute migraine with or without aura

Common side effects

• Dizziness
• Somnolence
• Nausea
• Paresthesia
• Chest discomfort

Key clinical trials

• Initiating Early Control of Migraine Pain and Associated Symptoms (PHASE3)
• Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) (PHASE3)
• Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT) (PHASE3)
• Maximizing Outcomes in Treating Acute Migraine (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AXS-07 (meloxicam-rizatriptan) CI brief — competitive landscape report
• AXS-07 (meloxicam-rizatriptan) updates RSS · CI watch RSS
• Axsome Therapeutics, Inc. portfolio CI